About: Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
Creator	Jiang, Shibo Lu, Lu Wang, Qian Atanasiu, Doina Wen, Yumei Su, Xiaojie Duzgunes, Nejat Kousoulas, Konstantin
Source	Medline; PMC
abstract	Infectious diseases caused by human immunodeficiency virus (HIV) and other highly pathogenic enveloped viruses, have threatened the global public health. Most antiviral drugs act as passive defenders to inhibit viral replication inside the cell, while a few of them function as gate keepers to combat viruses outside the cell, including fusion inhibitors, e.g., enfuvirtide, and receptor antagonists, e.g., maraviroc, as well as virus inactivators (including attachment inhibitors). Different from fusion inhibitors and receptor antagonists that must act in the presence of target cells, virus inactivators can actively inactivate cell-free virions in the blood, through interaction with one or more sites in the envelope glycoproteins (Envs) on virions. Notably, a number of protein- and peptide-based virus inactivators (PPVIs) under development are expected to have a better utilization rate than the current antiviral drugs and be safer for in vivo human application than the chemical-based virus inactivators. Here we have highlighted recent progress in developing PPVIs against several important enveloped viruses, including HIV, influenza virus, Zika virus (ZIKV), dengue virus (DENV), and herpes simplex virus (HSV), and the potential use of PPVIs for urgent treatment of infection by newly emerging or re-emerging viruses.
has issue date	2020-05-25(xsd:dateTime)
bibo:doi	10.3389/fmicb.2020.01063
bibo:pmid	32523582
has license	cc-by
sha1sum (hex)	8aba08824c1c37efcfd85ddfbe11e2db3c63f7d8
schema:url	https://doi.org/10.3389/fmicb.2020.01063
resource representing a document's title	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
has PubMed Central identifier	PMC7261908
has PubMed identifier	32523582
schema:publication	Front Microbiol
resource representing a document's body	covid:8aba08824c1c37efcfd85ddfbe11e2db3c63f7d8#body_text
is schema:about of	named entity 'inhibitors' named entity 'DENV' named entity 'Viruses' named entity 'NUMBER OF' named entity 'INFLUENZA VIRUS' named entity 'IN VIVO' named entity 'caused' named entity 'cell' named entity 'fusion' named entity 'Here' named entity 'Infectious diseases' named entity 'virus' named entity 'virus' named entity 'HIV' named entity 'presence' named entity 'Virus' named entity 'peptide-based' named entity 'inside the cell' named entity 'HSV' named entity 'HIV' named entity 'virus' named entity 'virions' named entity 'HIV' named entity 'virions' named entity 'infection' named entity 'enveloped viruses' named entity 'viruses' named entity 'passive' named entity 'CXCR4' named entity 'target sites' named entity 'N-terminal' named entity 'gate keepers' named entity 'hemagglutinin' named entity 'CD4 +' named entity 'binding affinity' named entity 'phage' named entity 'ion channel' named entity 'peptide-based' named entity 'infection' named entity 'Influenza viruses' named entity 'relapse' named entity 'immunogenicity' named entity 'receptor binding' named entity 'ectodomain' named entity 'pandemics' named entity 'IC50s' named entity 'viral titers' named entity 'D'Souza' named entity 'cryo-electron microscopy' named entity 'amino-acid' named entity 'Phe' named entity 'integrase inhibitors' named entity 'peptide' named entity 'viral capsid' named entity 'N-terminal' named entity 'pathogenic viruses' named entity 'zanamivir' named entity 'flaviviruses' named entity 'protein' named entity 'antibody' named entity 'peptides' named entity 'FDA' named entity 'cell membrane' named entity 'serotypes' named entity 'humanized mice' named entity 'protein' named entity 'membrane fusion' named entity 'lipid membranes' named entity 'protein' named entity 'virions' named entity 'conformation' named entity 'MAG' named entity 'PFI' named entity 'human pathogens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software